174688-78-9
174688-78-9 結(jié)構(gòu)式
基本信息
CYS-LYS-PHE-PHE-D-TRP-IAMP-THR-PHE-THR-SER-CYS
[DES-ALA1, DES-GLY2, DES-ASN5, D-TRP8, IAMP9]SOMATOSTATIN-14
Cys-Lys-Phe-Phe-D-Trp-IAMp-Thr-Phe-Thr-Ser-Cys (Disulfide bridge Cys3-Cys14)
物理化學(xué)性質(zhì)
| 報價日期 | 產(chǎn)品編號 | 產(chǎn)品名稱 | CAS號 | 包裝 | 價格 |
| 2025/12/22 | HY-P1206 | 生長抑素肽類似物 CH 275 | 174688-78-9 | 1 mg | 1305元 |
| 2025/12/22 | HY-P1206 | CH 275 | 174688-78-9 | 5 mg | 3960元 |
常見問題列表
IC50: 30.9 nM; Ki: 52 nM (somatostatin receptor 1)IC50: 345 nM (somatostatin receptor 3)
CH275 (100 nM) activates neprilysin activity, wheras treatment with cyclo-SRIF can complete this activation in vitro in primary neuron-based cell culture system, a mixture of wildtype hippocampal, cortical and striatal neuron.
CH275 (osmotic pump administration; 56 μM; two weeks) decreases the?level of neprilysin/SRIF in the App knock-in mice.CH275 directly injects into the Lacunosum molecular layer (Lmol) layer of 2-month-old App NL-G-F mice for four months. App NL-G-F mice begin to exhibit Aβ plaques at two months of age, but CH275 leads to robustly increased the expression of neprilysin in hippocampus which is paralleled by a clear reduction in Aβ plaque load in the same region, and without causing any toxic side effects.